Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer.

It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity.

[1][2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis.

TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.